it is the technology to direct the drug towards the location of cancer cells.and also drug can not harm to the normal cells.

1. Presented by-Swapnil Kale
Pharmaceutics
(M.Pharm sem-1st)
Department of Pharmaceutical Sciences R.T.M.N.U.,Nagpur-440033.

2.  Protein produced by B-lymphocyte
 Highley specific for binding
 Bind to the known structure of antigen

3.  Pro-moiety /pro-agent/bio reversible derivative
 1st used by Albert in1958
 Designed to overcome barrier by chemical approach instead
of formulation approach
 E.g. Human enzyme cacarboxypeptidaseA1+Methotrexate
(phenylalanine/tyrosine based)

4. Types of cancer therapies
 Radiotherapy-High energy radio beams are used to kill
cancer cells
 Surgery-removal of tumour by surgery
 Chemotherapy-Drugs are used in combinations to block
multiple cellular functions
 Targeted therapy-drugs are used against predetermined
cellular targets

5.  Acts as a cytotoxic agent generating system at tumour
site
 Reduce toxicity and increase selective toxicity at
tumour cells
 Principle
This therapy has three steps
1. Administration of antibody enzyme conjugate
2. Administration of clearing agent
3. Administration of prodrug molecule

6.  Need
 Improve cellular specificity
 Resistance to the normal cell growth
 Evolution of targeting
 In the 1980s decade(antibody drug conjugate prepared)
 MTDP-Molecular Targets Developing Programme run
by National Cancer Institute, USA.

7.  Stable, covalent linkage between enzyme and antibody
 Defined composition, molecular weight
 Antigen combining site ,enzyme active site must be free
 Act as Heterobifunctional coupling agent
 tumor associated antigen
 E.g.
Ovarian cancer-CA 125
Breast cancer- CA15-3

8.  What is the need??
 After specific time clearing agent will be administered
 Clearing agent clears the all AEC molecules
 In middle trials has been took place to remove this step
to make therapy easy

9.  Only after successful AEC clearance
 As it’s prodrug is inactive
 “Prodrug reach at door of every cell”
 Drug released by enzyme only at tumour cell

10. AEC will bind to the cancer cell
Clearance of AEC from blood
Highly cytotoxic pro-drug will reach all over
the body
Drug released only at tumour site

11. Chemotherapy
Kills all rapidly growing and
dividing cells
Same cells at intestinal
epithelium, line of digestive track,
bone marrow
Effect is dose dependant
ADEPT
Specify difference between normal cells and
cancerous cells
Fundamental difference is tumour cells
mutations are presents causing uncontrolled
proliferation
Defective proteins produced by these genes
are the prime targets
Comparison with chemotherapy

12.  Challenges
 Selection of enzyme with no human homologue also
with immune compatibility
 Skilled professionals
 Achievements
 New door has been opened for treatment cellular level
 Use of immunosuppression in short term use

13.  10.1016/j.addr.2017.09.009,by Surinder
K.Sharma
 Prodrug : challenges and Rewards , Part 1,By
Velentino J.Stella , Jefferson W.Tilley
 www.Wikipedia .com/antibody directed
enzyme prodrug therapy